|
|
|
Mozobil (plerixafor injection) is approved by the United States Food and Drug Administration (FDA) to be used with another agent granulocyte-colony stimulating factor (G-CSF), to mobilize stem cells into the peripheral blood for collection and subsequent autologous transplantation in patients with myeloma.
|
|
Publications
|
|
|
|
What it is, how it works, administration, benefits and risks on one easy to understand card. |
|
|
|
|
|
Published in Leukemia (2009), 1–9 |
|
|
|
|
|
Articles include:
* Plerixafor and Transplantation in Myeloma
* Phase II Study of Carfilzomib in Patients with Relapsed Myeloma
* IMWG Studies Patients Who Have Exhausted Their Treatment Options
* 2009 Kyle Award Given to Prof. Jean-Luc Harousseau
* Dr. Brian G.M. Durie Honored for Lifetime of Achievement in Myeloma
|
|
News about Mozobil
Links
|
back
print
back to top